Your account is not claimed yet. You can sign up with ORCID to claim your account.

Dan Cojocari

Years Active: 2020-2023
Publications (10 Years): 3

AbbVie Inc

University of Toronto (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

AbbVie Inc

United States

Senior Scientist :: Discovery Oncology

Education History

University of Toronto

Canada

PHD :: Medical Biophysics

Publications

Junichiro Yuda, Christine Will, Darren C Phillips, Linu Abraham, Cory Alvey, Abraham Avigdor, Wayne R Buck, Lauren Besenhofer, Erwin Boghaert, Dong Cheng, Dan Cojocari, Kelly Doyle, T Matthew Hansen, Kevin Huang, Eric F Johnson, Andrew S Judd, Russell A Judge, John C Kalvass, Aaron Kunzer, Lloyd T Lam, Rachel Li, Ruth L Martin, Anthony Mastracchio, Mike Mitten, Adam Petrich, Jin Wang, James E Ward, Haichao Zhang, Xilu Wang, Johannes E Wolff, Katherine M Bell-McGuinn, Andrew J Souers
Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. Communications medicine 3 (1) (2023)
Severine Cathelin, David Sharon, Amit Subedi, Dan Cojocari, Darren C Phillips, Joel D Leverson, Kyle J MacBeth, Brandon Nicolay, Rohini Narayanaswamy, Sebastien Ronseaux, Guowen Liu, Steven M Chan
Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia. Leukemia (2021)
Sha Jin, Dan Cojocari, Julie J Purkal, Relja Popovic, Nari N Talaty, Yu Xiao, Larry R Solomon, Erwin R Boghaert, Joel D Leverson, Darren C Phillips
5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (13) (2020)

Dan Cojocari.css-eqlu8i{font-size:small;padding-left:4px;}